Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mitchell Liu

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Medical Physics|April 10, 2012
Biological consequences of MLC calibration errors in IMRT delivery and QAVitali Moiseenko, Vincent Lapointe, Kerry James, et al.
International Journal of Radiation Oncology, Biology, Physics|October 4, 2005
Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mLEric Berthelet, Tom Pickles, Kenny Won Jae Lee, et al.
Journal of Medical Imaging and Radiation Sciences|May 5, 2019
The Distribution and Patterns of Practice of Stereotactic Ablative Body Radiotherapy in CanadaChad R Lund, Jeffrey Q Cao, Mitchell Liu, et al.
Journal of Breast Cancer|March 26, 2024
Five-Fraction High-Conformal Ultrahypofractionated Radiotherapy for Primary Tumors in Metastatic Breast CancerJeongshim Lee, Jee Hung Kim, Mitchell Liu, et al.
Radiation Oncology (London, England)|February 29, 2020
Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumorsYizhou Zhao, Eman Khawandanh, Steven Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2013
Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributionsMaria Thor, Aditya Apte, Joseph O Deasy, et al.
Cancer Letters|November 1, 2025
Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic diseaseJee Suk Chang, Florence T H Wu, Heejoo Ko, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 9, 2017
The impact of comorbidities on the benefits of prolonged androgen ablation in patients with T3-4 prostate cancer treated with external beam radiation therapyEric Tran, Matthew Paquette, Justin Jay, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2009
Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-upMira Keyes, Stacy Miller, Veronika Moravan, et al.
Brachytherapy|August 10, 2010
Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapyIngrid Spadinger, W James Morris, Mira Keyes, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Medical Physics|April 10, 2012
Biological consequences of MLC calibration errors in IMRT delivery and QAVitali Moiseenko, Vincent Lapointe, Kerry James, et al.
International Journal of Radiation Oncology, Biology, Physics|October 4, 2005
Long-term androgen deprivation therapy improves survival in prostate cancer patients presenting with prostate-specific antigen levels > 20 ng/mLEric Berthelet, Tom Pickles, Kenny Won Jae Lee, et al.
Journal of Medical Imaging and Radiation Sciences|May 5, 2019
The Distribution and Patterns of Practice of Stereotactic Ablative Body Radiotherapy in CanadaChad R Lund, Jeffrey Q Cao, Mitchell Liu, et al.
Journal of Breast Cancer|March 26, 2024
Five-Fraction High-Conformal Ultrahypofractionated Radiotherapy for Primary Tumors in Metastatic Breast CancerJeongshim Lee, Jee Hung Kim, Mitchell Liu, et al.
Radiation Oncology (London, England)|February 29, 2020
Outcomes of stereotactic body radiotherapy 60 Gy in 8 fractions when prioritizing organs at risk for central and ultracentral lung tumorsYizhou Zhao, Eman Khawandanh, Steven Thomas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|November 16, 2013
Dose/volume-response relations for rectal morbidity using planned and simulated motion-inclusive dose distributionsMaria Thor, Aditya Apte, Joseph O Deasy, et al.
Cancer Letters|November 1, 2025
Rethinking clinical trial endpoints for evaluating serially delivered 'strategic radiotherapy' in oligometastatic or oligoprogressive metastatic diseaseJee Suk Chang, Florence T H Wu, Heejoo Ko, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|July 9, 2017
The impact of comorbidities on the benefits of prolonged androgen ablation in patients with T3-4 prostate cancer treated with external beam radiation therapyEric Tran, Matthew Paquette, Justin Jay, et al.
International Journal of Radiation Oncology, Biology, Physics|February 13, 2009
Urinary symptom flare in 712 125I prostate brachytherapy patients: long-term follow-upMira Keyes, Stacy Miller, Veronika Moravan, et al.
Brachytherapy|August 10, 2010
Quadrant dosimetry as a predictor of biochemical relapse in 125I prostate brachytherapyIngrid Spadinger, W James Morris, Mira Keyes, et al.
Pageof 10